In human GCT cell lines, SMAD3 drives cell viability by activating NF-κB, which in turn up-regulates SMAD3 expression; this positive feedback loop activates the ERK1/2 pathway leading to increased GCT cell survival [21]. This evidence concerns the gene MAPK3 and granular cell tumor.